Pepine, C.J.

patient eptifibatide trial atrial fi brillation state infarction study pursuit 30 days death revascularization treatment effect treatment effect stroke therapy st-segment atrial syndrome placebo outcome 0.001 non-us patients eptifibatide therapy elevation brillation point non-u 6 months st-segment elevation /iiia month incidence event end point ischemic group management infusion surgery platelet reduction glycoprotein benefit study drug infusion patients randomized percutaneou randomized signi strategy range country investigator mortality high-dose eptifibatide study drug circulation population heparin 96 hours angina ͻ0.001 variable procedure hospital heart difference world america ischemic syndromes figure non-us sites receptor suppression cardiol pursuit trial table receptor predictor epti fibatide variability